A two-year clinical trial found that Medtronic's cardiac resynchronization therapy device combined with drug therapy was more effective in delaying the worsening of symptoms in patients with mild heart failure than using medication alone. The positive results could provide a boost to a larger study on CRT devices sponsored by Boston Scientific, an analyst said.

Related Summaries